Effects of Neuromuscular Block Reversal With Sugammadex vs Neostigmine on Postoperative Respiratory Outcomes After Major Abdominal Surgery
NCT02361060 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 130
Last updated 2017-02-23
Summary
Pulmonary complications are relatively frequent after surgery, and can be associated with an increase in morbidity and mortality. Although there are several causative mechanisms that can lead to postoperative pulmonary complications, alterations in the shape and motion of the chest wall are of primary importance.
In the investigator´s institution the incidence of postoperatory hypoxemia defined as pO2/FiO2 \<300 is over 20% for patients after major abdominal surgery.
Observational and randomized clinical trials have demonstrated that incomplete neuromuscular recovery during the early postoperative period may result in acute respiratory events (hypoxemia and airway obstruction) and an increased risk of postoperative pulmonary complications.
A recent study in laparoscopic bariatric surgery showed that patients in which neuromuscular block reversal was done with sugammadex had less chest X-ray pathological changes than those from an historical cohort reversed with neostigmine.
The hypothesis is that differences in pulmonary complications, as atelectasis and hypoxemia, between patients reverted with sugammadex or neostigmine may be more apparent with more sensitive techniques like spirometry or lung ultrasound when they exist.
Lung ultrasound (LUS) has demonstrated a sensitivity of 90% and a specificity of 98%, to detect alveolar consolidation in critical ill patients while chest radiography data are known to be imprecise.The investigator would like to explore the utility of LUS in postsurgical patients and the relationship between degree of hypoxemia and consolidation area.
Objectives:
1. Primary: Forced vital capacity decreases after surgery. This reduction may be relieved in the absence of residual neuromuscular block. Objective is to assess differences after reversal with neostigmine versus sugammadex in:
• Forced vital capacity (FVC)
2. Secondary objectives: To assess differences after reversal with neostigmine versus sugammadex in:
* Atelectasis size determined by lung ultrasound (Plannimetry)
* pO2/FiO2 \<300 1 hour after surgery
* Explore the accuracy of lung ultrasound (LUS) to diagnosis postoperative atelectasis and its correlation with chest Xray, FVC and pO2/FiO2.
Hypotheses:
1. Sugammadex NMB reversal results in a lower reduction of forced vital capacity (FVC) as compared to NMB reversal with neostigmine.
2. Atelectasis is common after major surgery. Size of atelectasis determined by lung ultrasound planimetry is lower one hour after sugammadex reversal as compared to the neostigmine group.
3. The incidence of post-surgical hypoxemia is lower in the sugammadex group as compared to the neostigmine group (Hypoxemia defined as pO2/FiO2 less than 300 is expected in 20% of patients after major abdominal surgery).
4. Lung ultrasound has a better capacity to detect alveolar consolidation than Chest Xray after major surgery.
5. Atelectasis size determine by planimetry has a good correlation with pO2/FiO2 and decrease of FVC after surgery
Conditions
- Major Abdominal Surgery
Interventions
- DRUG
-
Neostigmine
40mcg/kg
- DRUG
-
Sugammadex
4mg/kg
- DRUG
-
Atropine
10 mcg/kg
Sponsors & Collaborators
-
Enrique Alday Muñoz
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-02-28
- Primary Completion
- 2016-07-04
- Completion
- 2016-07-04
Countries
- Spain
Study Locations
More Related Trials
-
Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium
NCT03328312 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699)
NCT00724932 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetics and Pharmacodynamics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade
NCT04131218 ·Status: UNKNOWN ·Phase: PHASE4
-
Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Propofol Anesthesia
NCT07044180 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Neuromuscular Blockade and Surgical Conditions
NCT01564576 ·Status: UNKNOWN ·Phase: NA
-
Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028)
NCT00559468 ·Status: COMPLETED ·Phase: PHASE3
-
Remifentanil Without Muscle Relaxant for Thoracotomy
NCT02030808 ·Status: COMPLETED ·Phase: PHASE2
-
Serratus Plain Block Versus Paravertebral Block Versus Serratus Plain Block and Paravertebral Block for Postoperative Pain Following Thoracoscopic Surgery
NCT04222010 ·Status: COMPLETED ·Phase: PHASE3
-
Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in the Reversal of Profound Neuromuscular Blockade (P05767)
NCT00758485 ·Status: COMPLETED ·Phase: PHASE3
-
Dose Finding Study for Effective Reversal of a Deep Rocuronium-induced Neuromuscular Block With Sugammadex in Morbidly Obese Patients
NCT01911520 ·Status: COMPLETED ·Phase: PHASE2
-
Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023)
NCT00298831 ·Status: COMPLETED ·Phase: PHASE3
-
Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED)
NCT00751179 ·Status: COMPLETED ·Phase: PHASE3
-
Quality of Awakening and Impact on Cognitive Function After Administration of Sugammadex in Robotic Radical Cystectomy
NCT02454504 ·Status: COMPLETED ·Phase: NA
-
Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942)
NCT00379613 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of Sugammadex During Transcranial Electrical Motor Evoked Potential Monitoring in Spinal Surgery
NCT04471376 ·Status: COMPLETED ·Phase: NA
-
Erector Spinae Plane Block With Ropivacaine for Major Upper Abdominal Surgery
NCT04702685 ·Status: UNKNOWN ·Phase: PHASE3
-
Incidence and Severity of Residual Neuromuscular Blockade
NCT02660398 ·Status: COMPLETED ·Phase: PHASE4
-
The Impact of an Epidural Anesthetic on the Consumption of Sevoflurane in Major Abdominal Surgery
NCT04021264 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
Dose Finding Posterolateral Thoracotomy Study
NCT00807209 ·Status: TERMINATED ·Phase: PHASE2
-
Sugammadex ED90 Dose in the Obese Patients
NCT02568345 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).
NCT03519854 ·Status: COMPLETED ·Phase: PHASE2
-
Ropivacaine Plasma Concentrations After Fascial Blocks in Elective Cardio-thoracic and Abdominal Surgery
NCT05592691 ·Status: UNKNOWN
-
The Feasibility of Sugammadex for General Anesthesia in Patients Undergoing Kidney and Pancreas Transplantation Surgery
NCT04944303 ·Status: COMPLETED ·Phase: NA
-
Clinical Efficacy and Safety of Dexmedetomidine as an Adjuvant in Quadratus Lumborum Versus Epidural Block in Postoperative Lower Abdominal Cancer Surgeries
NCT06130670 ·Status: COMPLETED ·Phase: NA
-
Comparison of Recovery From Rocuronium 1.2 mg/kg Followed by Sugammadex (Org 25969) 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)(MK-8616-026)
NCT00474253 ·Status: COMPLETED ·Phase: PHASE3